Chembio Diagnostic Systems, Inc. – Trademark Portfolio
Entity Type: 03
Chembio Diagnostic Systems, Inc. holds 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 13 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 10 trademarks are registered and 2 are pending. Notable registered marks include DPP, CHEMBIO, STAT-PAK, STAT-VIEW, and SURE CHECK. The owner is based in Medford, NY.
3661 Horseblock Road
Medford, NY 11763
Showing of trademarks Trademarks
Trademark Classifications
Chembio Diagnostic Systems, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Chembio Diagnostic Systems, Inc. have?
Chembio Diagnostic Systems, Inc. has 16 U.S. trademarks filed with the USPTO. Of these, 10 registered, 2 pending, 2 abandoned, 2 cancelled.
What trademark classes does Chembio Diagnostic Systems, Inc. file in?
Chembio Diagnostic Systems, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Chembio Diagnostic Systems, Inc.'s most well-known trademarks?
Chembio Diagnostic Systems, Inc.'s registered trademark portfolio includes well-known marks such as DPP, CHEMBIO, STAT-PAK, STAT-VIEW, and SURE CHECK. These are among 10 currently registered trademarks in the portfolio.
What is Chembio Diagnostic Systems, Inc.'s trademark registration success rate?
Chembio Diagnostic Systems, Inc. has a 71% trademark registration rate, with 10 out of 14 resolved applications resulting in successful registration. Currently, 2 applications are pending review.